Press Releases

Media Inquiries - media@caredx.com

Date	Title and Summary	Additional Formats
Toggle Summary Mar 24, 2014	XDx Announces Appointment of Kenneth E. Ludlum as Chief Financial Officer	View HTML
Toggle Summary Mar 28, 2014	XDx Announces Name Change to CareDx	View HTML
Toggle Summary Apr 25, 2014	CareDx Announces Appointment of George W. Bickerstaff to Its Board of Directors	View HTML
Toggle Summary Jun 03, 2014	CareDx Files Registration Statement for Proposed Initial Public Offering	View HTML
Toggle Summary Jun 11, 2014	CareDx Completes Acquisition of ImmuMetrix	View HTML
Toggle Summary Jun 16, 2014	CareDx and Illumina Enter into Supply Agreement for Next Generation Sequencing Technologies	View HTML
Toggle Summary Jul 17, 2014	CareDx Announces Pricing of its IPO and Completion of its First Day of Trading CareDx Announces Pricing of its IPO and Completion of its First Day of Trading Brisbane, CA July 17, 2014 CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts.	View HTML CareDx Announces Pricing of its IPO and Completion of its First Day of Trading 11.8 KB
Toggle Summary Jul 28, 2014	CareDx Presents Cell-Free DNA Biomarker Results in Heart and Kidney Transplant Recipients at the World Transplant Congress Graft-Derived cfDNA in Bloodstream Correlates to Acute Cellular Rejection in Kidney as Well as in Heart Transplant Recipients	View HTML CareDx Presents Cell-Free DNA Biomarker Results in Heart and Kidney Transplant Recipients at the World Transplant Congress 22.1 KB
Toggle Summary Jul 31, 2014	CareDx and Allegheny General Hospital Launch Research Study of Novel Test to Screen Heart Transplant Recipients for Signs of Rejection BRISBANE, Calif. and PITTSBURGH , July 31, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA) a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients and Allegheny	View HTML CareDx and Allegheny General Hospital Launch Research Study of Novel Test to Screen Heart Transplant Recipients for Signs of Rejection 26.4 KB
Toggle Summary Aug 14, 2014	CareDx to Release Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 27, 2014 BRISBANE, Calif. , Aug. 14, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that it will	View HTML CareDx to Release Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 27, 2014 17.7 KB